This study highlights Luteolin's potential as a dual inhibitor of PDGFRα T674I and c-Kit D816H, mutations associated with drugresistance in gastrointestinal stromal tumors (GISTs). This evidence concerns the gene KIT and gastrointestinal stromal tumor.